- About Us
- Advertise
- Contact Us
- Editorial Info
- Editorial Advisory Board
- Do Not Sell My Personal Information
- Privacy Policy
- Terms and Conditions
© 2025 MJH Life Sciences™ and Pharmaceutical Technology. All rights reserved.
Featured Content
European Biotech Targeting Anti-ageing
Oct 2nd 2024
Novel mitophagy inducers and gene therapies that restore cellular function and decelerate the ageing process.
Why Are Pharmaceutical Companies Reluctant to Adopt Cloud Technologies?
Mar 4th 2024
Despite its understandable hesitancy, the pharma industry is facing a need for more widespread adoption of cloud-based solutions.
Training for Operational Excellence
Dec 3rd 2023
The bio/pharmaceutical industry is struggling with the challenge of staffing and training.
Billions of Reasons to be Buoyant
Sep 2nd 2023
Pharma's ability to continually reinvent itself will be critical in growing future business operations.
Latest Videos
Latest News
Roquette Announces Completion of Qualicaps Acquisition at AAPS PharmSci 360
October 25th 2023
The acquisition of Qualicaps reflects a strategic investment that aims to strengthen Roquette’s global standing in oral dosage solutions.
Royalty Pharma to Purchase up to $1.5 Billion of PTC Therapeutics’ Royalty on Roche’s Evrysdi
October 20th 2023
The spinal muscular atrophy treatment, currently marketed by Roche, generated $1.2 billion in sales in 2022.
Spark Therapeutics Partners with SpliceBio on a Gene Therapy for Eye Disease
October 18th 2023
Spark Therapeutics and SpliceBio have formed a collaboration to develop a gene therapy that can treat an inherited retinal disease.
CIRM Picks Forge Biologics as AAV Manufacturing Partner
October 18th 2023
The California Institute for Regenerative Medicine has partnered with Forge Biologics, which will manufacture AAVs to help accelerate gene therapy programs in California.
Innovative Start-Ups at CPHI Barcelona
October 15th 2023
The Start-Up Market at CPHI Barcelona will bring together 27 start-ups, innovators, and small enterprises from across the pharma landscape.
Cellares Expands Agreement with Bristol Myers Squibb for Second CAR-T Program
October 13th 2023
Under an expanded agreement, Cellares will provide proof-of-concept manufacturing for a second CAR-T cell therapy from Bristol Myers Squibb.
Bristol Myers Squibb Acquires Mirati Therapeutics for up to $5.8 Billion
October 12th 2023
Mirati’s focus on breakthrough cancer treatments will bolster Bristol Myers Squibb’s oncology portfolio.
Salipro Biotech and Icosagen to Collaborate on Antibody Discovery
October 12th 2023
Salipro Biotech and Icosagen have entered into a multi-target collaboration to discover and characterize monoclonal antibodies.
BIOVECTRA in Tech Transfer Agreement with Acuitas Therapeutics for LNP Delivery System
October 11th 2023
Under this agreement, Acuitas Therapeutics’ LNP technology platform will be transferred to BIOVECTRA for use in manufacturing mRNA-based therapies.
Roche to Develop Two Novel RNA-targeted Programs from Ionis for CNS Diseases
October 11th 2023
Roche will gain exclusive worldwide rights to develop, manufacture, and commercialize Ionis’ investigational RNA-based therapeutic candidates for Alzheimer's and Huntington's disease.